CareDx (NASDAQ: CDNA) secures preliminary approval for shareholder derivative settlement

Rhea-AI Filing Summary

CareDx, Inc. reports that a U.S. federal court has granted preliminary approval of a proposed settlement of a shareholder derivative lawsuit titled Edelman, et al. v. Bickerstaff, et al. The company previously reached an agreement in principle to resolve this case, and on December 9, 2025, the U.S. District Court for the Northern District of California issued an order preliminarily approving the settlement.

The Court also approved the form of notice to shareholders and scheduled a hearing on June 30, 2026 to consider whether to grant final approval of the proposed settlement. CareDx has filed the notice of pendency and proposed settlement and the full stipulation and agreement of compromise, settlement, and release as exhibits to this report.

0001217234FALSE00012172342025-12-182025-12-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 18, 2025

CAREDX, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-36536

94-3316839

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

8000 Marina Boulevard, 4th Floor

Brisbane, California 94005

(Address of Principal Executive Offices) (Zip Code)

(415) 287-2300

Registrant’s telephone number, including area code

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)

(Trading Symbol)

(Name of exchange on which registered)

Common Stock, $0.001 Par Value

CDNA

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 26, 2025, an unopposed motion for the preliminary approval of settlement was filed after CareDx, Inc. (the “Company”) reached an agreement in principle for a proposed settlement (the “Proposed Settlement”) of a shareholder derivative litigation, captioned Edelman, et al., v. Bickerstaff, et al., 3:25-cv-02036-TLT (N.D. Cal. filed Feb. 26, 2025). On December 9, 2025, the U.S. District Court for the Northern District of California (the “Court”) entered an order providing for preliminarily approval of the Proposed Settlement. In its order, the Court also approved the form of notice relating to the Proposed Settlement and set a hearing date of June 30, 2026 to consider whether to grant final approval of the Proposed Settlement.

Copies of the Notice of Pendency and Proposed Settlement of Shareholder Derivative Action and the Stipulation and Agreement of Compromise, Settlement, and Release, and the exhibits thereto, are attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Notice of Pendency and Proposed Settlement of Shareholder Derivative Action.

99.2 Stipulation and Agreement of Compromise, Settlement, and Release.

104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 18, 2025

CAREDX, INC.

By:

/s/ JOHN W. HANNA

John W. Hanna

Chief Executive Officer

(Principal Executive Officer)

FAQ

What did CareDx, Inc. (CDNA) disclose in this 8-K filing?

CareDx, Inc. disclosed that the U.S. District Court for the Northern District of California has granted preliminary approval of a proposed settlement of a shareholder derivative lawsuit involving the company.

What legal case is involved in CareDx, Inc. (CDNA)'s proposed settlement?

The proposed settlement relates to a shareholder derivative action captioned Edelman, et al., v. Bickerstaff, et al., 3:25-cv-02036-TLT, filed in the U.S. District Court for the Northern District of California.

When did the court grant preliminary approval of CareDx, Inc. (CDNA)'s settlement?

The Court entered an order providing for preliminary approval of the proposed settlement on December 9, 2025.

When is the final approval hearing for the CareDx, Inc. (CDNA) derivative settlement?

The U.S. District Court for the Northern District of California set a hearing date of June 30, 2026 to consider whether to grant final approval of the proposed settlement.

What documents related to the CareDx, Inc. (CDNA) settlement are attached to the filing?

The filing includes as exhibits the Notice of Pendency and Proposed Settlement of Shareholder Derivative Action (Exhibit 99.1) and the Stipulation and Agreement of Compromise, Settlement, and Release (Exhibit 99.2).

Does the CareDx, Inc. (CDNA) filing indicate that the settlement is final?

No. The filing states that the settlement has received preliminary approval. Final approval will be considered by the Court at the hearing scheduled for June 30, 2026.